press releases

Date Title
Sep 13, 2021 Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Sep 07, 2021 Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Sep 01, 2021 Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 09, 2021 Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Aug 03, 2021 Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Jul 29, 2021 Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
Jul 29, 2021 Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Jul 21, 2021 Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
Jun 30, 2021 Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Jun 24, 2021 Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

Sr. Director, Investor Relations & Corporate Communications 617-551-8276


Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?